• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Baxter BioPharma Solutions

    PCI Pharma Services

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    PCI Pharma Services

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    FDA’s Quality Agreements Guidance

    Evaluation of FDA’s recently issued Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry

    FDA’s Quality Agreements Guidance
    Related CONTENT
    • Symbiosis
    • Alcami
    • Hovione
    • A Potential “Marriage”
    • Mogene
    Paul Mason, Ph.D., Director of Lachman Consultant Services, Inc.01.26.17
    The recently issued FDA guidance for industry titled, “Contract Manufacturing Arrangements for Drugs: Quality Agreements,” (the “Quality Agreements Guidance”) states that the FDA considers that the owner’s—those who own and control a pharmaceutical material and engage the services of the contract facilities—Quality Unit responsibility includes approving or rejecting the contract facility’s product or service —parties that provide services on behalf of an owner. The services that can be outsourced to a contract facility can be varied: formulation, fill and finish, chemical synthesis, analytical testing, packaging and labeling etc.

    However, all such activities are critical to the quality and efficacy of the final product and the owner, when approving a contract facility, must ensure that the contract facility adheres to cGMP requirements. Indeed, within the Quality Agreements Guidance, it states that it is both the owner’s and contract facility’s responsibility to ensure compliance with cGMP for a drug product manufacturing operation, otherwise, a drug product may be considered to be adulterated.

    With the FDA issuing the Quality Agreement Guidance, there is recognition by the FDA that owners routinely utilize the services of contract facilities for various critical activities of drug manufacturing and that a critical tool to ensure a successful relationship between the owner and the contract facility is the Quality Agreement. As part of a comprehensive quality systems model, the owner should utilize a written quality agreement whenever engaging the services of a contract facility so that it is clear the respective cGMP related roles/responsibilities between the owner and contract facility for the services to be provided.

    The quality agreement should clearly describe the materials or services to be provided, quality specifications and define the communication mechanisms between owner and contract facility. The quality agreement should address items that have a potential to impact the quality of the contract facilities deliverable, such as: subcontracting by the contract facility; and addressing change to processes, equipment, methods, specification, records/data, etc. The FDA considers the quality agreement to be key in facilitating compliance with cGMP to those matters relating to 21 CFR 211.22, which states that quality unit activities and procedures should be in writing.

    The Quality Agreements Guidance builds upon ICH guidance titled, “Q10 Pharmaceutical Quality System,” which states that the owner is ultimately responsible for ensuring that “processes are in place to assure the control of outsourced activities and the quality of purchased material.” Risk management should be considered by the owner when approving a contract facility and when compiling the quality agreement. The FDA encourages both parties to utilize the concepts described in ICH guidance titled, “Q9 Quality Risk Management,” to ensure the most critical areas with the greatest potential impact to the drug product or active pharmaceutical ingredient are considered during contract facility approval and quality agreement implementation. When qualifying a potential contract facility, the owner must assess the suitability and competence via on-site audits—or other pre-defined qualification criteria—and continually assess the performance of “approved” contract facilities against pre-defined criteria, which, in turn, is driven by the quality needs of the outsourced activities.

    The primary goal of the quality agreement is to define between the owner or contract facility who has what cGMP responsibility in relation to those applicable CFR requirements such as 21 CFR parts 210, 211, 600-680, 820 and 1271. The Quality Agreements Guidance defines the elements of a quality agreement within the following sections: purpose/scope; definitions; resolution of disagreements; manufacturing activities and document lifecycle. The bulk of the quality agreement will specify the roles and responsibilities for the manufacturing and testing activities—the owner outsourced services—which is the most critical element of the quality agreement. It is imperative that the quality agreement clearly specifies which party is responsible for the specific activity and depending upon the nature of the outsourced activity will cover the following topics.

    Quality unit activities
    Within the quality agreement relating to quality activities, it should be clear how the owner and contract facility’s individual quality operations will collaborate to ensure the manufactured products that are impacted by the outsourced activity will be compliant with cGMP. It should be stressed within the quality agreement that the contract facility quality unit is responsible for rejecting or approving the deliverable from the contract facility, such as test results, in-process materials, etc., but the owner quality operations are ultimately responsible for approving or rejecting drugs, including final release, which have been impacted by the outsourced activity. The agreement should cover audits and the expectations relating to the communication of findings and the classification of findings that the owner needs to be aware of, such as, critical vs. major vs. minor. There should be provision to allow the owner to inspect the contract facility to ensure compliance with cGMP as part of routine verification of owner qualification of the contract facility.

    Facilities and equipment
    This will address the specifics of the contracted operations in relation to the actual sites and equipment that will be utilized by the contract facility and who has the responsibility for qualifying and maintaining the equipment and applicable systems along with validating the processes. This is to include all equipment and facilities that are needed to ensure the cGMP operations of the contracted operations, such as, information technology and automated control systems, environmental monitoring, utilities and room classification. A critical component for this section of the quality agreement is ensuring the defining of controls to prevent cross contamination when the contract facility processes drugs for multiple owners.

    Materials management
    This section of the quality agreement will define responsibility for the establishment of specifications for components and the qualification of component suppliers. In addition, it will address ownership for the sampling and testing of the components and inventory management and the necessary segregation and status control of materials. It should be clear within the agreement who has responsibility for physical control of materials at different points in the manufacturing process and ensuring proper conditions for storing and transporting materials.

    Product-specific considerations
    The agreement may include specific requirements relating to the product such as: product specifications; and product details relating to manufacturing operations, etc. Provisions should be included for knowledge transfer such as the transfer of development information from the owner to the contract facility and how the contract facility will keep the owner appraised of information gained through the outsourced activities.

    Laboratory controls 
    It is recommended that the quality agreement for contract testing references the procedures/processes by which all test results conducted by the contract facility are communicated to the owner for evaluation. The owner should have clear procedures on the review and approval of testing that is conducted by the contract facility and the mechanism for accessing the contract facilities raw data—hardcopies and e-records—as part of routine review by the owner.

    The agreement should also cover the mechanism for the transfer of analytical test procedures between the owner and contract facility. It is paramount that the quality agreement defines the procedures for the routine owner audit of the contract facility laboratory controls to provide assurance that the laboratory operates in a controlled state and in accordance with cGMP. Such auditing should include confirmation by the owner that the contract facility has a data integrity governance system. There should also be clear delineation of responsibility within the quality agreement for investigating deviations, discrepancies, and OOS/OOT results between the owner and contract facility.

    Documentation
    There should be clear delineation within the agreement for responsibility between the owner and contract facility for the review and approval of documents. This includes the review and approval of changes to contract facility procedures that will have an impact on the outsourced activities performed by the contract facility and the accessibility of all critical documentation for inspections/audits.

    It is imperative that change control is discussed within the quality agreement and the Quality Agreements Guidance provides direction for how owners and contract facilities should address changes to processes, facilities, equipment, test methods, etc. It should be explicitly stated within the quality agreement, what changes the owners need to review and approve and, correspondingly, what changes the contract facility must approve and a description of the notification process and timing. Depending upon the nature of the change it should be defined within the agreement how change controls are managed and who has what responsibility, such as conducting validation, updating the FDA, and the vehicle by which the agency is notified of changes to validated processes—supplement, annual report, etc. 

    Conclusion
    As more activities relating to drug product and active pharmaceutical ingredient (API) manufacturing are outsourced, the FDA recognizes the criticality of the quality agreement in ensuring the outsourced activity complies to cGMP requirements and ultimately meets the quality requirements of the impacted final drug product. Within the recently issued Quality Agreements Guidance, the FDA outlines clear expectations on what should be contained within the agreement to ensure responsibilities are defined between the owner and contract facility. 


    Paul Mason is a director in the science and technology practice at Lachman Consultants. With over 17 years of experience in the pharmaceutical industry, he is a quality control chemist experienced in sterile parenteral, API, and solid oral dosage forms. His experience spans finished dosage form, CMOs, and API intermediates manufacture support in both a quality control and analytical development setting. For further information relating to quality agreements please contact the author at p.mason@lachmanconsultants.com, or James Davidson at j.davidson@lachmanconsultants.com.
    Suggested For You
    Symbiosis Symbiosis
    Alcami Alcami
    Hovione Hovione
    A Potential “Marriage” A Potential “Marriage”
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    The FDA and Metrics The FDA and Metrics
    Establishments, Identifications, Submissions and Beyond Establishments, Identifications, Submissions and Beyond
    Trump Picks New FDA Commish Trump Picks New FDA Commish
    Elemental Impurities: A Virtual Company Perspective Elemental Impurities: A Virtual Company Perspective
    Diteba Develops IV Approach to Achieve Biowaiver Status Diteba Develops IV Approach to Achieve Biowaiver Status
    Piramal Pharma Solutions Appoints CCO Piramal Pharma Solutions Appoints CCO
    Generic Drug Trends Generic Drug Trends
    Whither Washington? Whither Washington?

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login